Ryght AI and CRSA partner to improve cancer trials for patients in South Australia
US-based clinical research software company Ryght AI has partnered with Cancer Research South Australia (CRSA) to advance cancer clinical trials…
All articles by
-
-
Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints
US-based biopharmaceutical company Kashiv Biosciences has reported that a Phase I trial of its 125mg/mL pre-filled syringe injection, KSHB002, has…
-
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial
US-based pharmaceutical company 60 Degrees Pharmaceuticals has received approval from the investigational review board (IRB) for a Phase II trial…
-
Akero’s cirrhosis treatment shows promise in Phase IIb study
Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) in individuals…
-
Fortress doses first subject in Phase II CMV vaccine trial
Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial…
-
Roche reports positive topline outcomes from DMD treatment trial
Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys (delandistrogene…
-
Tisento doses first subject in Phase IIb study of zagociguat for MELAS treatment
Tisento Therapeutics has dosed the first subject in its Phase IIb PRIZM study, examining the effects of the oral investigational…
-
Pfizer reports positive outcomes from trial of mCRC combination therapy
Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for treating metastatic…
-
Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight individuals.…
-
Traws Pharma completes Phase I trials of H5N1 bird flu treatment drug
Traws Pharma has completed the Phase I clinical trials of tivoxavir marboxil, a single-dose drug for treating or preventing H5N1…